Recently, eight years of hard research, kernel independent development of treatment with biological products category drugs - injection with recombinant carboxypeptidase G2 get issued by the administration of state food and drug supervision and administration of the drug approval documents of clinical trials. In the current biological medicine review under the situation of increasingly strict, the success of the product is approved for this team of technical level and excellent persistence once again. So far, this team has won three biological drugs for testing, further rich biological medicine research and development of product line.

    Recombinant carboxypeptidase G2 is a cancer treatment drug, as domestic exclusive varieties, filled the domestic in the high-dose methotrexate chemotherapy after poisoning rescue of blank, brought the Gospel to the cancer patients. Compared with current treatments, pioneered by the drug treatment method has significant advantages, has opened up domestic indications in the treatment of precedent. High-dose methotrexate chemotherapy for osteosarcoma, leukemia and lymphoma cancer such as first-line treatment method, has the very good curative effect, but some patients may be life-threatening toxic reaction caused by various reasons. Kernel development for injection recombinant carboxypeptidase G2, but under the premise that does not influence the effect of chemotherapy, to methotrexate rapid degradation of a plasma to eduction body outside, non-toxic metabolites avoid toxic reaction.

    After eight years of technical research, this product in the aspect of drug preparation, preparation formula obtained independent intellectual property rights, significantly reduce the production cost and improves the product quality. At present, listed in the United States similar products market price of more than 300000 yuan. At present, the company is actively promoting clinical research and industrialization development. This product after, can greatly reduce cost, greatly improves the patient to a drug accessibility. A conservative estimate, the drug in the domestic market potential of more than 5 billion yuan/year.